Roche's Vabysmo Shows Positive Vision Improvement in Diverse Populations with Diabetic Macular Edema

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced positive topline one-year results from the open-label, single-arm phase IV ELEVATUM study evaluating Vabysmo&r...

October 21, 2024 | Monday | News
Amicus Therapeutics and Teva Pharmaceuticals Reach License Agreement on GALAFOLD®

Amicus Therapeutics (Nasdaq: FOLD) announced that it has entered into a License Agreement (Agreement) with Teva Pharmaceuticals USA, Inc. and Teva Pharmace...

October 18, 2024 | Friday | News
MSD's Clesrovimab Shows Promising Results in Protecting Infants from RSV in Phase 2b/3 Trial

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the presentation of positive results from the Phase 2b/3 clinical trial ...

October 18, 2024 | Friday | News
Innovent Biologics Announces Successful Phase 2 Results for Picankibart in Treating Ulcerative Colitis

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

October 17, 2024 | Thursday | News
Alnylam Pharmaceuticals Submits Type II Variation for Vutrisiran to Treat ATTR Amyloidosis with Cardiomyopathy

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, announced the submission of a Type II Variatio...

October 17, 2024 | Thursday | News
InSphero and FDA Publish Landmark Study on Liver Toxicology Using 3D InSight™ Microtissues

 InSphero, the global leader in 3D cell culture technology, and scientists from the U.S. Food and Drug Administration's (FDA) National Cente...

October 16, 2024 | Wednesday | News
Jazz Pharmaceuticals Reports Positive Phase 3 Results for Zepzelca® Combined with Atezolizumab in Small Cell Lung Cancer

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced positive top-line results from the Phase 3 clinical trial evaluating Zepzelca® (lurbinected...

October 16, 2024 | Wednesday | News
Amgen Announces Positive Phase 3 Results for UPLIZNA® in Generalized Myasthenia Gravis, Paving the Way for New Treatment Options

Amgen (NASDAQ:AMGN) announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the efficacy and safety of UPLIZNA&...

October 16, 2024 | Wednesday | News
Eli Lilly's Mirikizumab Shows Promising Histologic Response in Phase 3 Study for Crohn's Disease, Outperforming Ustekinumab

Eli Lilly and Company (NYSE: LLY) announced data demonstrating more patients with moderately to severely active Crohn's disease treated with miri...

October 15, 2024 | Tuesday | News
BD and Hamilton Robotics Launch Automation-Ready Reagents to Transform Genomic Sequencing Workflows

  Automation-Ready Reagents Used with the Hamilton Robotics Liquid-Handler Streamlines and Helps Accelerate Lab Work Leading to Genomic Sequencing&nb...

October 15, 2024 | Tuesday | News
PacBio Partners with Singapore’s National Cancer Centre to Advance Cancer Research in Asia

PacBio , a leading developer of high-quality, highly accurate sequencing solutions,  announced the signing of a new Research Collaboration Agre...

October 14, 2024 | Monday | News
Aileron Therapeutics Showcases Promising LTI-03 Results for Idiopathic Pulmonary Fibrosis at ICLAF

Aileron Therapeutics,  a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs i...

October 14, 2024 | Monday | News
Cell Signaling Technology Launches InTraSeq™ for Revolutionary Single-Cell Protein and RNA Quantification

Simultaneously and reliably quantify proteins, including post-translational modifications (PTMs), in a single-cell RNA sequencing (RNA-seq) assay using...

October 09, 2024 | Wednesday | News
NovaCina Expands Perth Facility with Advanced SA25 GMP Filling Line to Enhance Global CDMO Services

NovaCina, a global contract development and manufacturing organization (CDMO), has today announced the expansion of its facility in Perth, Australia with...

October 08, 2024 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close